CD33 and acute myeloid leukemia: Alternative treatments like the CD33 chimeric antigen receptor (CAR)-based T-cell treatment that targets CD33, combined with allogeneic hematopoietic cell transplantation (HSCT) (Kenderian et al., 2015; Walter, 2018; Bhatt, 2019) may also be used to treat AML.